G1 Therapeutics to Present Additional Trilaciclib Phase 2 Small Cell Lung Cancer Data at 2019 American Society of Clinical On...
May 16 2019 - 6:00AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology
company, today announced that additional findings from a Phase 2
clinical trial demonstrating the myelopreservation benefits of
trilaciclib in 2nd/3rd-line small cell lung cancer (SCLC) patients
will be featured as an oral presentation at the upcoming 2019
American Society of Clinical Oncology (ASCO) Annual Meeting. The
presentation will take place on June 1, 2019 at 3:00 p.m. CT at the
McCormick Place Convention Center in Chicago, Illinois.
Trilaciclib is a first-in-class myelopreservation agent designed
to protect the bone marrow from damage by chemotherapy and improve
patient outcomes.
“Chemotherapy remains an important treatment in the fight
against cancer, however it has serious side effects, including
damaging the patient’s bone marrow. We are pleased to present
further findings that show the addition of trilaciclib to
chemotherapy can protect the bone marrow from damage in those
undergoing treatment for SCLC,” said Raj Malik, M.D., Chief Medical
Officer and Senior Vice President, R&D. “We look forward to our
pre-NDA and pre-MAA meetings later this year with U.S. and European
regulatory authorities as we work to bring trilaciclib to market
for SCLC patients and continue to explore how trilaciclib may help
those with other types of cancer.”
Details on the presentation are listed below and are also
available on the 2019 ASCO Annual Meeting website:
http://abstracts.asco.org/.
Title: Effect of trilaciclib, a CDK 4/6
inhibitor, on myelosuppression in patients with previously treated
extensive-stage small cell lung cancer receiving
topotecan.Abstract Number:
8505Session: Lung Cancer – Non-Small Cell
Local-Regional/Small Cell/Other Thoracic CancersDate and
Time: Saturday, June 1, 2019, 3:00-3:15 p.m.
CTLocation: Hall D2, McCormick Place Lakeside
Center Level 3Presenter: Lowell Hart., M.D.,
Scientific Director of Research, Florida Cancer
Specialists
About TrilaciclibTrilaciclib is a
first-in-class myelopreservation agent designed to protect the bone
marrow from damage by chemotherapy and improve patient outcomes. G1
plans to submit marketing applications in the U.S. and Europe for
trilaciclib for myelopreservation in SCLC in 2020. These
submissions will be based on currently available data from three
randomized, double-blind, placebo-controlled SCLC clinical trials,
as well as safety data collected across all completed and ongoing
clinical trials.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and delivery of innovative therapies that improve the
lives of those affected by cancer. The company is advancing three
clinical-stage programs. Trilaciclib and lerociclib are designed to
enable more effective combination treatment strategies and improve
patient outcomes across multiple oncology indications. G1T48 is a
potential best-in-class oral selective estrogen receptor degrader
(SERD) for the treatment of ER+ breast cancer. G1 also has an
active discovery program focused on cyclin-dependent kinase
targets.
G1 is based in Research Triangle Park, N.C. For additional
information, please visit www.g1therapeutics.com and follow us on
Twitter @G1Therapeutics.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
"may," "will," "expect," "plan," "anticipate," "estimate," "intend"
and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking
statements in this news release include, but are not limited to,
the therapeutic potential of trilaciclib, lerociclib and G1T48 and
the timing for next steps with regard to the trilaciclib marketing
applications, and are based on the Company’s expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties.
Factors that may cause the Company’s actual results to differ from
those expressed or implied in the forward-looking statements in
this press release are discussed in the Company’s filings with the
U.S. Securities and Exchange Commission, including the "Risk
Factors" sections contained therein and include, but are not
limited to, the Company’s ability to complete clinical trials for,
obtain approvals for and commercialize any of its product
candidates; the Company’s initial success in ongoing clinical
trials may not be indicative of results obtained when these trials
are completed or in later stage trials; the inherent uncertainties
associated with developing new products or technologies and
operating as a development-stage company; the Company’s development
of a CDK4/6 inhibitor to reduce chemotherapy-induced
myelosuppression is novel, unproven and rapidly evolving and may
never lead to a marketable product; and market conditions. Except
as required by law, the Company assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Contact:Jeff MacdonaldHead of Investor
Relations/Public
Relations919-907-1944jmacdonald@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Sep 2024 to Oct 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Oct 2023 to Oct 2024